Southeastern Cancer Research Association ninth annual meeting October 15–16,1981 Howard University Cancer Center Washington, D.C.

1982 ◽  
Vol 10 (1) ◽  
pp. 97-97
Keyword(s):  
Cancer Research ◽  
Annual Meeting ◽  
Cancer Center ◽  
Research Association ◽  
Howard University

INCIDENCE OF RESPIRATORY SYSTEM CANCER IN THE TOMSK REGION (2005-2016)

2018 ◽  
Vol 64 (6) ◽  
pp. 732-738
Author(s):  
Yevgeniy Choynzonov ◽  
Lyubov Pisareva ◽  
Liliya Zhuykova ◽  
Olga Ananina ◽  
Irina Odintsova
Keyword(s):  
Cancer Research ◽  
Survival Rate ◽  
Respiratory System ◽  
Incidence Rates ◽  
Vital Role ◽  
Cancer Center ◽  
Cancer Research Institute ◽  
Cancer Register ◽  
Common Cancer ◽  
Tomsk Region

Respiratory system cancer (cancer of the nasal cavity, middle ear, paranasal sinuses (C30-31), larynx (C32), trachea, bronchi and lung (C33-34) is one of the most common malignancies in the Tomsk region, comprising 12.9% of all cancer cases. The purpose of the study was to analyze the respiratory system cancer incidence among the population of the Tomsk region. Materials and methods. The study was based on cancer register data collected at the Cancer Research Institute and Tomsk Regional Cancer Center, and covered the period 2005-2016. Results. Respiratory system cancer is the most common cancer in men, comprising 21.7% and the 6-th most common cancer in women, comprising 5.1. The incidence of respiratory system cancer decreased in men and showed an increasing tendency in women. The age-standardized incidence rates in the Tomsk region were expected to be 58.3 per 100,000 males and 12.8 per 100,000 females by 2020. Conclusion. Early detection and prediction of respiratory system cancer should play a vital role in the diagnosis process and also increase the survival rate of patient.

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

2002 ◽  
Vol 20 (24) ◽  
pp. 4628-4635 ◽  
Author(s):  
W. Jonat ◽  
M. Kaufmann ◽  
W. Sauerbrei ◽  
R. Blamey ◽  
J. Cuzick ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Side Effects ◽  
Association Study ◽  
Early Breast Cancer ◽  
Research Association ◽  
Node Positive ◽  
Er Positive ◽  
Premenopausal Patients ◽  
Positive Breast Cancer

PURPOSE: Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term toxic effects and long-term effects associated with premature menopause. PATIENTS AND METHODS: The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823) for adjuvant treatment in premenopausal patients with node-positive breast cancer. RESULTS: Analysis was performed when 684 events had been achieved, and the median follow-up was 6 years. A significant interaction between treatment and estrogen receptor (ER) status was found (P = .0016). In ER-positive patients (approximately 74%), goserelin was equivalent to CMF for disease-free survival (DFS) (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.84 to 1.20). In ER-negative patients, goserelin was inferior to CMF for DFS (HR, 1.76; 95% CI, 1.27 to 2.44). Amenorrhea occurred in more than 95% of goserelin patients by 6 months versus 58.6% of CMF patients. Menses returned in most goserelin patients after therapy stopped, whereas amenorrhea was generally permanent in CMF patients (22.6% v 76.9% amenorrheic at 3 years). Chemotherapy-related side effects such as nausea/vomiting, alopecia, and infection were higher with CMF than with goserelin during CMF treatment. Side effects related to estrogen suppression were initially higher with goserelin, but when goserelin treatment stopped, reduced to a level below that observed in the CMF group. CONCLUSION: Goserelin offers an effective, well-tolerated alternative to CMF in premenopausal patients with ER-positive and node-positive early breast cancer.

Sign in / Sign up

Export Citation Format

Share Document